Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism

<p>Abstract</p> <p>Background</p> <p>Philadelphia positive leukemias are characterized by the presence of Bcr-Abl fusion protein which exhibits an abnormal kinase activity. Selective Abl kinase inhibitors have been successfully established for the treatment of Ph (+) leukemias. Despite high rates of...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Khateb Mamduh, Ruimi Nili, Khamisie Hazem, Najajreh Yousef, Mian Afsar, Metodieva Anna, Ruthardt Martin, Mahajna Jamal
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2012-11-01
coleção:	BMC Cancer
Assuntos:	Philadelphia chromosome Bcr-Abl “gatekeeper” mutation T315I Allosteric inhibition Abl kinase inhibitors
Acesso em linha:	http://www.biomedcentral.com/1471-2407/12/563
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!